Published on Feb 6, 2023
As of December 29, 2022, and pursuant to Section 1262 of the Consolidated Appropriations Act of 2023, federal law no longer requires prescribers to obtain a DATA-Waiver or X-Waiver to prescribe medications, like buprenorphine, to treat patients with opioid use disorder. Read joint statement from DBHDS, DMAS and DHP on the removal of DATA Waiver (X-Waiver) requirement.
Virginia Board of Pharmacy
Email: pharmbd@dhp.virginia.gov
Caroline D. Juran, Executive Director
R. Dale St. Clair, Jr., Chairman